Emerging resistance to TB drugs poses challenges for global health initiatives.
- Rifampin-resistant tuberculosis (RR-TB) is a significant contributor to global antimicrobial resistance, with a high mortality rate.
- A lack of access to rapid drug susceptibility testing for TB is a critical issue in reducing inappropriate treatment.
- A potential pan-TB treatment approach offers a universal regimen without the need for drug susceptibility testing, but emerging resistance poses a risk.
- Modeling the use of a pan-TB regimen showed initial improvements in treatment outcomes but a decline in effectiveness over time due to increasing resistance.
- Introduction of pan-TB regimens meeting current targets is likely to improve population-wide outcomes initially, but ongoing assessment and adjustments will be necessary to counter emerging resistance for continued effectiveness.
Source link
Infectious Diseases, Pulmonary Medicine, Pharmacists, Public Health & Prevention